INTRODUCTION
Over one-third of the world’s population has been exposed to hepatitis B virus (HBV) and it is estimated that there are 350 million chronic carriers worldwide. Reactivation of HBV is best characterized as a virological event in which there is a sudden increase in viral replication. Frequently, there is a concomitant elevation in serum aminotransferase levels and bilirubin levels in severe cases. While HBV reactivation can also occur spontaneously, the most common clinical setting involves the use of chemotherapeutic or immunosuppressive drugs. Such agents are now often used in hematologic, gastrointestinal, rheumatic, dermatologic and pulmonary diseases as well as in transplantation. Hepatitis B virus reactivation with imatinib, a tyrosine kinase inhibitor (TKI), has been reported in chronic myeloid leukemia (CML). Nilotinib is a more potent second generation TKI and it inhibits the Src-family kinase LCK and hamper proliferation and function of CD8 (+) T lymphocytes. CD8 (+) T lymphocytes are the main cellular subset responsible for viral clearance in patients with HBV infection. We report a case of HBV reactivation under treatment with nilotinib. Fatal HBV reactivation is not usually related to death in chronic myeloid leukemia patients who have an expectation of longevity with well-tolerated oral drugs. Thus, screening for latent chronic HBV infections including assessment of hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc antibody) and antibody to hepatitis B surface antigen (anti-HBs), especially at countries with intermediate and high prevalence of HBsAg is warranted. Treatment with nucleoside analogs and close monitoring may be life-saving in this context.

CASE REPORT
A 59-year-old female patient was admitted to our hospital with elevated white blood cell count and hepatosplenomegaly in January 2014. Her medical history revealed arterial hypertension, diabetes mellitus, subtotal thyroidectomy and cholecystectomy. She was receiving metformin 500 mg/day for diabetes mellitus and perindopril 5 mg/day plus indapamide 1.25 mg/day for hypertension. In physical examination, thyroidectomy scar was observed and liver was 4 cm and spleen was 7 cm palpable. Hemoglobin level was 12.6 g/dl, white blood cell count was 98.7 × 10^9/l, absolute neutrophil count was 87.4 × 10^9/l and platelet count was 363 × 10^9/l. Biochemical parameters including renal and liver function tests were normal except glucose, uric acid and lactate dehydrogenase. According to her laboratory and peripheral blood examination she was thought to have CML. The diagnosis was confirmed by conventional cytogenetics, FISH and PCR tests. Sokal risk was calculated.

1Department of Gastroenterology, Eskisehir Osmangazi University, Eskisehir, Turkey
2Department of Hematology, Eskisehir Osmangazi University, Eskisehir, Turkey
3Department of Internal Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey

Address reprint requests to: Safak Meric Ozgenel, Research Assistant, Department of Gastroenterology, Eskisehir Osmangazi University, Eskisehir, Turkey, Phone: 902222392979, e-mail: mozgenel@ogu.edu.tr
as 0.97 (intermediate risk). Imatinib 400 mg/day was started in February 2014. Hepatitis B surface antigen (HBsAg) positivity and diagnosis of chronic inactive hepatitis B was determined 4 years ago at a random check-up with positivity of HBsAg, hepatitis B e antigen (HBe Ag) and antibody to hepatitis B core antigen (anti-HBc) and negativity of HBV DNA. Prior to treatment with imatinib, HBsAg, HBeAg and anti HBc IgG results were positive and HBV DNA was negative. There was no recommendation for pre-emptive treatment to patients receiving TKI at that time. Also, health insurance agency did not provide prophylactic therapy for patients receiving TKA and thus prophylactic therapy was not initiated and monitoring for HBV reactivation was planned. BCR/ABL1 transcript was <1% and complete cytogenetic response was obtained 6 months after imatinib therapy. However, BCR/ABL1 transcript level began to increase progressively after sixth month and the therapy was changed to nilotinib 800 mg/day in December 2014. One week later, she complained about fatigue, anorexia, nausea and vomiting. Her physical examination revealed icteric sclera. Complete blood count was normal. Biochemical tests showed elevated alanine aminotransferase (ALT) (42 U/L, normal range 0–41 U/L), total bilirubin (4 mg/dl, normal range 0.1–1.1 mg/dl) and direct bilirubin (1.6 mg/dl, normal range 0–0.3 mg/dl) levels. Nilotinib was stopped because of grade 3 hyperbilirubinemia. Bilirubin levels were normal 1 week later but transaminase levels continued to increase (AST: 61 U/L, normal range 0–40 U/L, ALT: 68 U/L). Nilotinib was not started and she was called for a new visit 1 week later. In this visit, AST was 152 U/L and ALT was 195 U/L. She denied herbal medicine and alcohol intake. New viral hepatitis serology and polymerase chain reaction tests revealed HBsAg, HBeAg anti HBe IgG and HBV DNA positivity with a viral load of 3.14 × 10^5 IU/ml. Anti-HBs IgG, anti-HBe IgG, anti-HDV IgG, anti-HBc IgM, HDV antigen, anti HCV IgG and HCV RNA tests were negative. Abdominal ultrasound showed liver was 168 mm, liver parenchyma was coarse and liver contour was mildly irregular. Tenofovir was started and transaminase levels returned to normal within the first month. Nilotinib was restarted and she is going well with no clinical and laboratory abnormalities and HBV DNA levels are negative under tenofovir treatment.

**DISCUSSION**

Hepatitis B virus reactivation is characterized by an abrupt rise of HBV DNA in patients with previously inactive or resolved HBV infection during or closely after chemotherapy. The current generally accepted definition of HBV reactivation following chemotherapy is the development of hepatitis with a serum ALT greater than three times the upper limit of normal or an absolute increase of 100 IU/L, associated with a demonstrable HBV DNA increase by at least 10-fold of the basal pretreatment levels.\(^{11,12}\) Hepatitis B virus reactivation not only occur in HBsAg positive patients but this may also take place in HBsAg negative patients with anti-HBe IgG positivity and/or anti-HBs IgG positivity.\(^{13,14}\)

Imatinib is a TKI that blocks the ATP binding site of BCR/ABL and is currently recommended as the first line therapy for CML. Nilotinib is a second generation TKI and was designed to overcome imatinib resistance with a better efficacy.\(^{15}\) Hepatotoxicity has been reported with TKIs, however liver dysfunction usually resolves with either dose reduction or discontinuation of the drug. The mechanism of TKI-induced HBV reactivation remains unclear. *In vitro* studies have shown that imatinib can inhibit T-cell activation\(^{16}\) and proliferation.\(^{17}\) Nilotinib inhibits the Src-family kinase LCK and can hamper the proliferation and function of CD8 (+) T lymphocytes.\(^{18,19}\)

Hyperbilirubinemia is a well-known side-effect of nilotinib. As increment in bilirubin levels have returned to normal grades after stopping nilotinib and did not increase despite the progressive increase in AST and ALT levels; it can be suggested that the hyperbilirubinemia might be a side effect of the treatment, the elevations of AST and ALT are also may be attributed with the hepatotoxic effect of TKIs. However, the progressive elevation in AST and ALT levels despite discontinuation of the drug, resolution of clinical findings, normalization of AST and ALT levels, negativity of HBV DNA levels after tenofovir treatment and the progress of bilirubin levels within normal ranges after restart of nilotinib therapy suggest us that the reason of hyperbilirubinemia and increment at aminotransferase levels may be due to reactivation of HBV.

Although pre-emptive treatment with nucleoside/nucleotide analogs (NAs) before immunsuppressive treatment or anticancer cytotoxic chemotherapy is recommended,\(^{20,21}\) there was no recommendation on whether NAs should be given in patients undergoing TKI therapy till the e-publication of American Gastro-enterological Association (AGA) guidelines for the prevention and treatment of HBV reactivation during immune-suppressive drug therapy at October 2014. HBsAg positive/anti-HBc IgG positive or HBsAg negative/anti-HBc IgG positive patients treated with TKI are defined as moderate-risk group with anticipated incidence of HBV reactivation to 1 to 10% of cases and AGA suggests antiviral prophylaxis over monitoring for patients at moderate risk undergoing immune-suppressive drug therapy with weak recommendation; moderate-quality evidence.\(^{22}\) CD8 T cells are
the main cellular subset responsible for viral clearance in patients with HBV infection. Tyrosine kinase inhibitor may hamper the proliferation and function of CD8 (+) T lymphocytes. Antiviral prophylaxis to patients treated with TKI (suppressors of CD8 T cells, the main cellular subset responsible for viral clearance at patients with HBV inhibitors) can be life-saving in CML patients who have an expectation of longevity with well-tolerated oral drugs.16-23

CONCLUSION

Our case highlights the importance of HBV reactivation in CML patients receiving second generation TKIs. Fatal HBV reactivation should not be the cause of death in CML patients who have an expectation of longevity with well-tolerated oral drugs. Screening for latent chronic HBV infections with HBsAg, anti-HBc IgG, anti-HBs IgG, especially at countries with intermediate and high prevalence of HBs Ag, and pre-emptive treatment with NAs at patients with HBsAg, anti-HBc IgG positivity and close follow-up might be life-saving.

ACKNOWLEDGMENT

The work conforms to the provisions of the declaration of Helsinki and the written consents of the subjects have been acknowledged.

All authors have been participated at data analysis/interpretation, drafting article, critical revision of article, approval of article.

REFERENCES

1. Schilsky ML. Hepatitis B '360'. Transplant Proc 2013;45(3):982-985.
2. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis. World J Gastroenterol 2013;19(44):7880-7888.
3. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013;33(2):167-177.
4. Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF. The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C. Br J Dermatol 2013;169(6):1295-1303.
5. Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013;19(8):1318-1321.
6. Wang YD, Cui GH, You Y, Li M, Xia J, Hu Y. Reactivation of chronic hepatitis B infection related to imatinibmesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review. Zhonghua Xue Ye Xue Za Zhi 2012;33(9):743-746. (Article in Chinese)
7. Wang YD, Cui GH, Li M, Gowrea B, Xia J, Hu Y. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J 2012;125(14):2636-2637.
8. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010;42(3):843-845.
9. Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009;90(3):383-337.
10. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate therapy. Leuk Lymphoma 2006;47(1):155-157.
11. Yeow W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2010;62(3):299-307.
12. Yeow WI, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90(7):1306-1311.
13. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy pathogenesis and management. Rev Med Virol 2001;11(5):287-299.
14. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22(3):117-126.
15. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukemia. Best Pract Res Clin Haematol 2009;22(3):395-407.
16. Seggewiss R, Loret K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105(6):2473-2479.
17. Cwynarski K, Taylor R, Macchiarello E, Goldman J, Lombardi G, Melo JV, Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004;18(8):1332-1339.
18. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999;17(1):394-398.
19. Ridduejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinib-induced fatal acute liver failure. World J Gastroenterol 2007;13(48):6608-6611.
20. American Association for the Study of Liver Disease. AASLD clinical practice guidelines: chronic hepatitis B. Hepatol 2009;50(3):1-38.
21. European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57(1):167-185.
22. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falc-Ytter YT. American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterol 2015;148(1):215-219.
23. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006;87(pt6):1439-1449.